This presentation discusses nasal drug delivery systems. Some key points:
- Nasal delivery provides a non-invasive alternative to injections and direct access to systemic circulation. It offers improved bioavailability over oral administration for some drugs.
- Drugs administered via the nose can act locally in the nasal cavity or be absorbed systemically. The nose is also being investigated for direct nose-to-brain delivery of drugs.
- Various dosage forms exist for nasal delivery including drops, sprays, powders, gels and suspensions. Newer developments include compressed air nebulizers and bi-directional nasal devices.
- Factors influencing nasal absorption and formulations were discussed such as viscosity modifiers, absorption enhancers,
Administration of drug through nasal route is referred as Nasal drug delivery system.
Nasal administration is a route of administration in which the drug are insufflated through the nose for either local or systematic effect.
Nasal route is an alternative to invasive administrations and provides a direct access to the systemic circulation.
Penetration Enhancers:
Mechanism:
Inhibit enzymatic activity
Reduce mucus viscosity
Reduce MCC
Open tight junctions
Solubilize the drug
Nasopulmonary drug delivery system: Introduction to Nasal and Pulmonary routes of drug delivery, Formulation of Inhalers (dry powder and metered dose), nasal sprays, nebulizers
Nasal Drug Delivery System is a type of delivery system in which the nasal cavity is being used for delivery of medicine. It provides pathway to transfer drug directly to brain by bypassing Blood Brain Barrier through olfactory nerves. My case study is on the delivery of anti-Parkinson disease drug that is dopamine treatment through nasal route .
Introduction to Nasal drug delivery system,Anatomy of Nasal cavity,Advantages n limitataions of Nasal DDS,Mechanism,factors affecting Nasal DDS,Formulation,methods to enhance Nasal DDS,Dosage forms,Evalaution
In ancient time Ayurvedic system of medicine used nasal route for administration of drugs and the process is called as “Nasya”.
Nasal route has been used for local effects of decongestants but, in recent time it is being considered as a preferred route of drug delivery for systemic bioavailability.
Various proteins & peptides have shown a good bioavailability through this route.
INTRODUCTION
✓ Nasal Drug Delivery System is administration of drug through Nasal route.
✓ Nasal mucosa has been considered as a potential route of administration to achieve faster & higher level of drug absorption.
Ideal & non-invasive alternative to the parenteral route for systemic drug delivery; since it offers a truly "Needleless" drug delivery.
This route has been a convenient and reliable route.
Several new formulations are used to deliver drugs to the brain by olfactory, neuronal, and trigeminal pathways.
NOSE BRAIN PATHWAY
The olfactory mucosa (smelling area in nose) is in direct contact with the brain & CSF.
Medications absorbed across the olfactory mucosa directly enter the brain.
✓ This is termed as nose brain pathway which offers a rapid, direct route for drug delivery to the brain.
NOSE BRAIN PATHWAY.
Another way of drug absorption is through Trigeminal Nerve Pathway with the help of Pons.
✓ Besides the direct nose-to-brain pathways, there are other routes for the drugs to penetrate the brain.
✓ Such as from the respiratory route, drug can be transported partially to the circulation & reach the brain by the "nose-to-blood-to- brain" pathway.
Administration of drug through nasal route is referred as Nasal drug delivery system.
Nasal administration is a route of administration in which the drug are insufflated through the nose for either local or systematic effect.
Nasal route is an alternative to invasive administrations and provides a direct access to the systemic circulation.
Penetration Enhancers:
Mechanism:
Inhibit enzymatic activity
Reduce mucus viscosity
Reduce MCC
Open tight junctions
Solubilize the drug
Nasopulmonary drug delivery system: Introduction to Nasal and Pulmonary routes of drug delivery, Formulation of Inhalers (dry powder and metered dose), nasal sprays, nebulizers
Nasal Drug Delivery System is a type of delivery system in which the nasal cavity is being used for delivery of medicine. It provides pathway to transfer drug directly to brain by bypassing Blood Brain Barrier through olfactory nerves. My case study is on the delivery of anti-Parkinson disease drug that is dopamine treatment through nasal route .
Introduction to Nasal drug delivery system,Anatomy of Nasal cavity,Advantages n limitataions of Nasal DDS,Mechanism,factors affecting Nasal DDS,Formulation,methods to enhance Nasal DDS,Dosage forms,Evalaution
In ancient time Ayurvedic system of medicine used nasal route for administration of drugs and the process is called as “Nasya”.
Nasal route has been used for local effects of decongestants but, in recent time it is being considered as a preferred route of drug delivery for systemic bioavailability.
Various proteins & peptides have shown a good bioavailability through this route.
INTRODUCTION
✓ Nasal Drug Delivery System is administration of drug through Nasal route.
✓ Nasal mucosa has been considered as a potential route of administration to achieve faster & higher level of drug absorption.
Ideal & non-invasive alternative to the parenteral route for systemic drug delivery; since it offers a truly "Needleless" drug delivery.
This route has been a convenient and reliable route.
Several new formulations are used to deliver drugs to the brain by olfactory, neuronal, and trigeminal pathways.
NOSE BRAIN PATHWAY
The olfactory mucosa (smelling area in nose) is in direct contact with the brain & CSF.
Medications absorbed across the olfactory mucosa directly enter the brain.
✓ This is termed as nose brain pathway which offers a rapid, direct route for drug delivery to the brain.
NOSE BRAIN PATHWAY.
Another way of drug absorption is through Trigeminal Nerve Pathway with the help of Pons.
✓ Besides the direct nose-to-brain pathways, there are other routes for the drugs to penetrate the brain.
✓ Such as from the respiratory route, drug can be transported partially to the circulation & reach the brain by the "nose-to-blood-to- brain" pathway.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Nasal drug delivery system.pdf
1. Presentation on
Nasal Drug Delivery System
Submitted to – Presented by -
Dr. Rekha Rao Anusha
Assistant Professor M.Pharmacy
(Pharmaceutics) 2nd sem
Roll no.220121220014
GURU JAMBHESHWAR UNIVERSITY OF SCIENCE AND TECHNOLOGY
HISAR -125001
2. INTRODUCTION
➢ Administration of drug through nasal route is referred as Nasal drug
delivery system.
➢ Nasal route is an alternative to invasive administrations and provides a
direct access to the systemic circulation.
➢ Intranasal Medication administration offers a truly “Needleless ” solution
delivery.
➢ In recent years many drugs have been shown to achieve better systemic
bioavailability through nasal route than by oral administration.
➢ Nasal therapy, has been recognized form of treatment in the Ayurvedic
systems of Indian medicine, it is also called “NASAYA KARMA”.
2
3. • Drugs are administered to the nasal cavity for
a) localized
b) systemic action
c) vaccine delivery
d) possible direct nose brain delivery
ADVANTAGES
1. A non invasive route.
2. Hepatic first pass metabolism is absent.
3. Rapid drug absorption.
4. Quick onset of action.
5. The bioavailability of larger drug molecules can be improved by
means of absorption enhancer or other approach.
3
4. 6. The nasal bioavailability for smaller drug molecules is good.
7. Conventional route when compared with parenteral route for long term
therapy.
DISADVANTAGES
1. The absorption enhancers used to improve nasal drug delivery systems may
have histological toxicity which is not yet clearly established.
2. Absorption surface area is less when compared to GIT.
3. Once the drug is administered can not be removed.
4. Nasal irritation
4
5. ANATOMY & PHYSIOLOGY OF NASAL CAVITY
• The nasal cavity is divided into two halves by the nasal septum and
extends posterior to the nasopharynx, while the most anterior part of
the nasal cavity, the nasal vestibule, opens to the face through the
nostril.
• The nasal cavity consists of three main regions:
1) Nasal vestibule
2) Olfactory region
3) Respiratory region
5
7. The respiratory region contain three nasal turbinates the superior,
middle and the inferior, which project from the lateral wall of each half
of the nasal cavity.
In non-olfactory area includes-the nasal vestibule, covered with skin –
like stratified squamous epithelium cells.
In respiratory region, it has typical airways in the epithelium covered
with numerous microvilli, resulting in a large surface area available for
drug absorption and transport.
7
8. Mucus layer is propelled in a direction from the anterior towards the
posterior part of the nasal cavity.
The goblet cells are present in the mucus membrane which covers the
nasal turbinate and the atrium. It secretes mucus as mucus granules
which swell in the nasal fluid to contribute to the mucus layer.
Composition-
95% water, 2% mucin, 1% salts, 1% of proteins such as albumin,
immunoglobulins, lysozyme and lactoferrin and 1% lipids.
The mucus secretions give immune protection against inhaled bacteria
and viruses.
The pH of nasal secretion is 5.5-6.5 in adults and 5.0-6.7 in infants.
8
9. The respiratory tract, which includes
❑nasal
❑mucosa
❑Hypo pharynx
❑ large airways
❑small airways
provides a relatively large mucosal
surface area of approx. 100 m2
(in normal adult) for drug
absorption
9
10. TYPES OF NASAL DRUG DELIVERY
LOCAL DRUG DELIVERY
NOSE TO BRAIN DRUG DELIVERY
SYSTEMIC DRUG DELIVERY
10
11. Local Drug Delivery
➢It is a logical delivery choice for local (or topical) treatment.
➢Prominent examples are decongestants for nasal cold symptoms and
antihistamines and corticosteroids for allergic rhinitis.
➢Examples of nasal products with widespread use in this area include
the histamine, the anti-cholinergic agent Ipratropium bromide and
steroidal anti inflammatory agents.
11
13. Nose to Brain Drug delivery
➢Nose to brain drug delivery presents a promising alternative enabling
the delivery of therapeutic drugs to the CNS, while bypassing the
blood-brain barrier (BBB).
➢It is a non-invasive method , to access the CNS directly through the
olfactory or trigeminal nerves.
➢Improve therapy outcomes and to reduce side effects.
13
15. Systemic Drug delivery
❖Positive attributes of systemic delivery includes:
➢A relatively large surface area for drug absorption.
➢Rapid drug onset.
➢No first-pass metabolism.
➢Non-invasiveness.
15
17. Mechanism of drug absorption
❖Paracellular mechanism-
➢Process in which drug transported between cell and transcytosis by
vesicle carrier.
➢It is a slow process, in which passive diffusion take place.
❖Transcellular mechanism-
➢Process in which drug diffuse through a membrane.
➢It is an active transport process.
❖Via trigeminal Nerves-
➢Compounds that may be absorbed by the trigeminal nerve are transported
to the ganglion, where they enter the brain.
➢The transportation of molecules from the nasal cavity to the parenchyma
of the brain occurs along both the olfactory or trigeminal nerves.
17
20. Nasal Drops
• Nasal drops are one of the most convenient & simple
systems for nasal delivery. These are instilled into the
nose by dropper.
• Aqueous oily solutions, since the later inhibit the
movement of cilia in the nasal mucosa. If kept for
longer periods, may reach the lungs & cause lipoid
pneumonia.
• Nasal drops should be isotonic having neutral pH &
viscosity similar to nasal secretions by using
methylcellulose.
E.g.:- ephedrine nasal drops B.P.C, Otrivin nasal drops.
20
21. Nasal Spray
• These are aqueous or alcoholic preparations.
Applied to the mucous membrane of nose by
atomizer.
• Only fine droplets are required so they may reach
the lungs. By using metered pumps & actuators a
nasal spray can deliver an exact dose from 25 to
200µm.
e.g.:- adrenaline & atropine spray B.P.C
21
22. Nasal Powder
➢Dry powders are less frequently used in
nasal drug delivery.
➢Major advantage of this dosage form are
the lack of preservatives and the improved
stability of the formulation.
➢Compared to solutions, the administration
of powder could result in prolonged contact
with the nasal mucosa.
E .g:- sinu air nasal powder
22
23. Nasal Gels
1. Nasal gels are high-viscosity thickened solutions
or suspensions.
2.Without special application techniques, it only
occupies a narrow distribution area in the nasal
cavity, where it is placed directly.
3.Reduction of taste impact due to reduced
swallowing.
4. Reduction of irritation by using emollient.
23
24. Nasal Vaccines
• Nasal mucosa is the first site of contact with
inhaled antigens and therefore , it is used for
respiratory infections.
• Nasal vaccination is a promising alternative to
the parenteral route , because it is able to
enhance the systemic levels of specific
immunoglobulin G & immunoglobulin A.
E.g : Nasal vaccines against influenza A & B Virus
24
25. Compressed air nebulizer
➢ A nebulizer is a device used to
administer medication in the form
of a mist inhaled into the lungs.
➢ The compressed air is filling into
the device, so it is called
compressed air nebulizers.
25
27. Liposomes:-
• These are phospholipid vesicles
composed by bilayer enclosing one or
more aqueous compartments, in these
compartment drugs can be entrapped
or adsorbed.
27
28. Microsphere:-
➢Microsphere has an important role in
nasal drug delivery.
➢Enhancing absorption, sustained
release.
➢It protects the drug from enzymatic
degradation.
28
29. Pressurized MDI:-
➢A metered-dose inhaler (MDI) is a
device that delivers a specific amount
of medication to the lungs, in the
form of a short burst of aerosolized
medicine that is inhaled by the
patient.
➢Propellants in MDIs typically make up
more than 99 % of the delivered
dose.
29
30. Dry powder inhaler
➢ Dry powder inhalers are devices
through which a dry powder
formulation is delivered for local or
systemic effect via the pulmonary
route.
➢ Dry powder inhalers are bolus drug
delivery.
30
31. Metered-dose pump spray
• Most of the pharmaceutical
nasal preparations on the
market containing solutions,
emulsions or suspensions are
delivered by metered-dose
pump spray.
31
33. 1. VISCOSITY MODIFIERS
• These agents increase the viscosity of solution prolonging the
therapeutic activity of preparation.
• Highly viscous formulations interfere with the normal functions like
ciliary beating or muco-ciliary clearance and thus alter the
permeability of drug.
e.g.: hydroxy propyl cellulose, Carbopol, Cellulose agents, Dextran,
Chitosan, etc.
33
34. 2.SOLUBILIZERS
• Aqueous solubility of drug is always a limitation for nasal drug
delivery.
• e.g.: glycol, alcohol, labrasol, transcutol(diethylene glycol monoethyl
ether), small quantities of alcohol, surfactant.
• In such cases surfactants or cyclodextrins (HP- β -cyclodextrin) are
used , these serve as a biocompatible solubilizer & stabilizer in
combination with lipophilic absorption enhancers.
34
35. 3. SURFACTANTS
Modify the permeability of nasal mucosa & facilitate the nasal
absorption of drugs.
E.g. SLS, Poly acrylic acid, sod. glycolate
4. PRESERVATIVES
These are used to prevent the growth of microorganisms.
e.g.: parabens, benzalkonium chloride, phenyl ethyl alcohol, EDTA etc.
35
36. 5. BIOADHESIVE POLYMERS
• Increases the residence time of drug in nasal cavity and a higher local
drug concentration in the mucus lining on the nasal mucosal surface
• E.g.: Methylcellulose, Carboxy methylcellulose Hydroxyl propyl
cellulose
36
37. 6. ANTIOXIDANTS
• These are used to prevent drug oxidation.
• E.g.: sodium meta bisulphite , sodium bisulfite, butylated hydroxy
toluene& tocopherol etc.
7. ABSORBTION ENHANCERS
(a) Surfactants: Sodium glycolate, Sodium deoxycolate
(b) Chitosan
(c) Cyclodextrins Hydroxypropyl-ß-cyclodextrin, Dimethyl-ß-
cyclodextrin
(d) Complexing agents: EDTA
(e) Fatty acid salts: Oleic acid ,Caprylic acid, Lauric acid
(f) Phospholipids: L-α- lyso-phosphatidyl choline
(g) Fusidates: Sodium taurodi-hydro-fusidate
37
38. EVALUATION OF NASAL FORMULATION
➢ To improving the efficiency and effectiveness of active principles,
formulations and devices, another important objective of pharmaceutical
research is improving the link between in-vitro test data and in vivo
performance.
➢In vitro nasal permeation study:-
o In vitro diffusion study
o In-vivo nasal absorption study
➢Ex vivo nasal perfusion model
38
39. In Vivo Nasal Absorption studies
• Animal models for nasal absorption studies The animal models
employed for nasal absorption studies can be two types, viz., whole
animal or in vivo model and an isolated organ perfusion or ex vivo
model,
• 1.RAT MODEL
• 2.RABBIT MODEL
39
40. In vitro nasal permeation studies
(diffusion):
• The nasal diffusion cell is fabricated in glass.
• The lid has 3 opening, each for sampling,
thermometer, and a donor tube chamber.
• The nasal mucosa of sheep was separated &
stoned in distilled water containing few drops at
gentamycin injection. Mucosal surface is
attached to donor chamber tube.
• The donor chamber tube is placed such a way
that it just touches the diffusion medium in
recipient chamber. At predetermined intervals,
samples (0.5 ml) from recipient chamber are
with draw and transferred to amber colored
ampoules. The samples are estimated for drug
content by suitable analytical technique .
40
41. In Vivo Nasal Absorption studies:
1. Rabbit model
• Rabbit is anaesthetized by intramuscular injection of a
combination of ketamine and xylazine.
• The rabbit's head is held in an upright position and the
drug solution is administered by nasal spray each nostril.
• The blood samples are collected by an indwelling
catheter in the marginal ear vein.
During the experiment the body temperature of the rabbit
is maintained at 37°C with the help of a heating pad.
41
42. 2. Rat model
• The rat is anaesthesized. An incision is made in the
neck and the trachea is cannulated with a
polyethylene tube. Another tube is inserted through
the oesophagus towards the posterior region of the
nasal cavity.
• The drug solution is delivered to the nasal cavity
through the nostril or through the cannulation
tubing.
The blood samples are collected from the femoral
vein.
42
43. RECENT ADVANCEMENT IN NASAL DRUG DELIVERY
➢Firstly, during exhalation the soft palate closes automatically, separating
the nasal and oral cavities.
➢Secondly, during the closure of the soft palate, there is a communication
pathway between the two nostrils.
➢The device is inserted into one nostril by a sealing nozzle and the patient
blows into the mouthpiece.
➢The combination of closed soft palate and sealed nozzle creates an air-flow
that enters one nostril, turns 180° through the communication pathway
and exits through the other nostril (bidirectional flow).
➢By adding an exit resistor to give additional control of the input pressure, it
is possible to optimize distribution to the sinuses and the middle ear.
43
46. Applications
1.Delivery of non-peptide pharmaceuticals
Ex. Progesterone, estradiol, propranolol
2.Delivery of peptide based pharmaceuticals
Eg. Insulin, Calcitonin, Pituitary hormones etc.
3.Delivery of Diagnostic Drugs
Phenolsulfonphthalein – kidney function.
Secretin –pancreatic disorders
Pentagastrin – secretory function of gastric acid
46
47. 4. Delivery of drugs to Brain:
For treatment of Parkinson’s disease, Alzheimer disease.
For delivery of MSH, ACTH, Insulin to brain.
5. Delivery of vaccines
The nasal mucosa is the first site contacts with inhaled pathogens. The
nasal passages are rich in lymphoid tissue. Creation of both mucosal
and systemic immune responses. Low cost, patient friendly, non-
injectable ,safe.
47
48. References:
❑Alnasser Sulaiman, “ A review on nasal drug delivery system and its contribution in therapeutic
management.” Asian journal of pharmaceutical and clinical research,2019,2-3.
❑https://www.google.com/search?q=nasal+delivery+monkey+model&tbm=isch&ved=2ahUKEwiq2
JHu1P32AhUS_TgGHQxMC7AQ2-
cCegQIABAC&oq=nasal+delivery+monkey+model&cp=ChJtb2JpbGUtZ3dzLXdpei1pbWcQAzoHCC
MQ7wMQJzoECB4QClCMBVjPF2CiHWgAcAB4AIABzQGIAdkOkgEFMC45LjGYAQAQHAAQE&sclient
=mobile-gws-wiz-img&ei=RplMYqodkvrj4Q-MmK2ACw&bih=758&biw=412&client=ms-android-
samsung-gj-rev1&prmd=niv
❑https://www.researchgate.net/publication/490102_Nasal_drug_delivery_system_-_an_overview
❑https://www.researchgate.net/publication/41038_Intranasal_Drug_Delivery_How_Why_and_Wh
at_for
❑Sharma K Pramod, Garg Garima and Mohd Salim,“ Review on nasal drug delivery system with
recent advancement.” International Journal of Pharmacy and Pharmaceutical Sciences.2011,1-3.
48